SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Archive — January 2026
Page 2 of 5 of this archive, newest first.
A shortage listing ends. 21 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The glycaemic panel before treatment: what is worth measuring and when
The assay is not the problem. The interpretation of a lagging integral as a current measurement is the problem.
Who signed this, and what did they undertake by signing it
Accreditation is granted for a defined scope of methods. A laboratory can be properly accredited and the test on your certificate can sit outside it.
A supplier suspends shipping to Turkey after 15 consecutive customs detentions
The route did not close because of a rule about peptides.
What a 26% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
VendorInvestigate result on a Zhuhai retatrutide lot lands 1.8 points above the supplier’s stated figure
A reminder that a purity figure is the output of a method, and that methods differ.
Italy health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
Diminishing returns, quantified
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
What changing your injection day does to retatrutide exposure, and what it does not
What the pharmacokinetic data supports about dose timing, missed doses and interruption.
Janoshik, Medutest, PeptideMeter, VendorInvestigate: a capability audit
Four independent services underpin confidence in this market. All four are competent at chemistry. Microbiology is a different accreditation, a different facility and a…
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The United Kingdom declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Reading a barrel: the graduation that is not the one you think
Dead space in the needle hub is a real and calculable loss, and it matters more at small volumes than anybody expects.
What changed at SGN in January, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Brazil caps exenatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The submitted sample: the weakest link in the whole system
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
Why VendorInvestigate can tell you the mass is right and not that the sequence is
The Journal’s standing position: a mass that matches is necessary evidence of identity and nowhere near sufficient.
Singapore health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
BCH names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What the new South Africa guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Shanghai: 24 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Hydration, protein and the two failures that compound each other
The intervention with the clearest evidence is the one nobody frames as an intervention: adjusting the dose.
What happens when the drug is taken away: three randomised answers
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 8 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of Halvard & Pike Apothecary of Portland, Maine
A proper account of an operation that existed, and of what closing it cost.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The badge economy, and what it is actually certifying
Every step between the laboratory report and the product page removes information, and the badge is the last step.
A supplier suspends shipping to Ireland after 5 consecutive customs detentions
The route did not close because of a rule about peptides.
The 25-day notice: how a compounding wind-down works in Denmark
The document is four pages. Three of them are about dates.
The consolidator trading as Meridian Freight Partners closes after 21 years
A proper account of an operation that existed, and of what closing it cost.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Reading HbA1c in the presence of anaemia
HbA1c integrates roughly three months of glycaemia with the most recent weeks weighted most heavily. Almost every misreading of it is a misreading of that weighting.
Adverse events by dose, adverse events by week
Almost every figure in circulation about tolerability comes from six publications. This is what they say.